/

ATHE

Alterity Therapeutics LimitedClosed

2.85+0.01 +0.35%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 2.75 −3.51%

Open

2.94

Prev close

2.84

Day range

2.802.95

52-week range

2.665.89

Volume

14.56K0.85×

Mkt cap

51.89M

P/E ttm

—

Fwd P/E

-2.98

EPS ttm

-0.9000

Div yield

0.00%

Earnings

—

From 52w high

−51.61%

Price Chart

Yahoo Finance · delayed

ATHEOct 13, 2026O 2.94H 2.95L 2.80C 2.85−0.08 (−2.73%)Vol 19.00K

SMA 504.08
SMA 2004.04

1Y change −38.84% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ATHE Alterity Therapeutics Limited · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −15.43%
1 month: −29.63%
3 months: −43.34%
6 months: −21.27%
Year to date: −7.47%
1 year: −38.84%

Valuation & ownership

Market cap: 51.89M
Enterprise value: 14.77M
P/E (ttm): —
Forward P/E: -2.98
PEG ratio: —
Price / book: 1.74
Price / sales (ttm): 14.37
EV / EBITDA: -0.59
EPS (ttm): -0.9000
EPS (forward): -0.9577
Beta (5y monthly): -0.01
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 18.21M
Float: 14.43M
Short % of float: 0.14%
Short ratio (days): 1.68
Held by insiders: 0.00%
Held by institutions: 2.06%
Avg volume (3m): 17.06K
50-day average: 4.12
200-day average: 4.04
52-week change: −38.84%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 28.9
vs 50-day SMA: −30.22%
vs 200-day SMA: −29.44%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 9.54%
Realised vol (20d, ann.): 75.9%
From 52-week high: −51.61%
From 52-week low: +7.14%

ANR

Analyst Consensus

4 analysts

Consensus

—

Mean target

13.25

+364.91% implied

Low 10.00Median 13.50High 16.00

Recommendation trend

Now4 / 0 / 0
1m ago4 / 0 / 0
2m ago

DES

About Alterity Therapeutics Limited

Yahoo Finance profile

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Sector: Healthcare
Industry: Biotechnology
Employees: 11
Headquarters: Melbourne, VIC, Australia
Website: alteritytherapeutics.com
Officers: Dr. David A. Stamler M.D. CEO, MD & Director
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. CFO & Company Secretary
Dr. Rudolph Emile Tanzi Ph.D. Chief Scientific Advisor and Member of Research & Development Advisory Board

SEAS

Seasonality · ATHE

2007–2026 · monthly returns

Strongest month Jan +11.51%Weakest month Oct −6.35%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	2.9	8.5	1.2	30.5	-9.3	30.3	-17.7	1.6	-18.7	-21.9			−7.5%
2025	45.0	-21.3	-8.7	0.3	30.1	-9.1	23.7	-2.4	-23.9	12.0	-14.5	-14.4	−6.9%
2024	-15.3	-11.4	10.7	1.4	-11.0	-3.2	-11.6	-6.9	-12.1	-12.2	22.6	134.8	+32.9%
2023	11.7	-17.9	-13.4	0.7	3.9	-4.1	3.9	-6.2	-8.8	-6.0	-22.3	37.6	−28.9%
2022	30.6	-9.6	-2.4	-10.8	-9.5	-9.0	-1.6	-6.7	-21.4	-11.4	-7.7	-2.8	−51.4%
2021	23.1	-3.0	-10.0	0.7	-7.6	-3.0	-0.8	5.4	-6.6	-3.9	-20.5	-25.8	−46.3%
2020	1.3	-24.1	0.0	16.7	-17.1	105.2	22.7	61.0	-14.0	-38.6	22.6	-11.8	+71.8%
2019	25.0	0.6	16.8	-8.5	-23.8	0.0	-22.9	10.9	1.8	1.8	-20.7	-15.2	−39.1%
2018	-16.7	2.7	-20.2	-9.4	7.3	-8.7	6.9	3.0	-3.4	-7.5	-10.2	-23.4	−59.0%
2017	54.0	-12.7	42.9	1.6	-34.0	9.0	22.3	-4.6	4.9	9.3	6.9	-4.6	+91.4%
2016	-26.4	13.2	-21.1	29.2	3.3	25.1	-3.0	14.3	-14.1	-34.7	-16.3	-34.0	−62.3%
2015	-6.1	-27.9	0.9	4.5	17.1	-14.6	0.9	-20.3	-4.3	-4.4	14.0	-26.5	−56.1%
2014	65.5	-2.5	-75.2	-36.8	9.0	17.6	-3.5	2.3	-4.5	-14.0	-12.0	1.2	−76.6%
2013	-0.5	-3.7	7.6	-2.6	1.4	3.6	45.7	47.3	-17.5	9.7	8.9	42.8	+218.6%
2012	12.9	7.8	-5.6	-5.3	-5.0	3.3	-3.2	9.2	42.8	18.6	-11.7	-11.3	+49.7%
2011	0.8	22.2	82.5	-15.3	-17.6	-2.6	-3.7	-4.9	-11.4	-1.3	-2.0	-2.0	+17.6%
2010	1.5	10.4	-10.8	33.3	-18.7	-21.7	16.1	-12.3	2.6	12.0	9.2	-12.6	−5.3%
2009	18.4	-46.7	8.3	19.2	-6.5	-17.2	24.2	34.2	-6.0	-16.5	2.5	-18.0	−30.5%
2008	-5.0	18.7	-2.4	-3.6	-5.7	-6.7	15.8	-10.9	-9.1	-38.0	-9.7	-3.1	−52.5%
2007	-1.3	-8.0	8.7	5.0	0.0	-5.7	-5.4	-8.2	5.8	4.8	-16.8	68.1	+31.6%

ATHE

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ATHE

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Alterity Therapeutics Limited

Seasonality · ATHE

Insider Activity · ATHE

Congress Trades · ATHE

Investors Holding ATHE

Investors Holding ATHE

Congress Trades · ATHE

Insider Activity · ATHE

Seasonality · ATHE

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Alterity Therapeutics Limited

Financial Snapshot

Earnings & Dividends

News